Feasability of Point of Care advanced blood analysis
2M already developed the platelet counter a device which is now being commercialized. Within the FirstBlood project we would like to explore the opportunities based on the existing technology platform of what else is possible. We would like to bring a solution to market that is versatile, fast, easy and affordable in establishing a complete view on or diagnosis of a person’s blood. Based on this view we would like to see inflammation or bacterial infection at an early stage. Also diseases like osteoporosis and other diseases can possible be early diagnosed. Within the FirstBlood project we looked at the technological and economical opportunities and risks based on desk research, market research and interviews with potential partners, experiments and early stage developments.
This project was made possible by a contribution from the European Regional Development Fund as part of MIT-Zuid. For more information see EFRO.